TL;DR Verdict
Wegovy (semaglutide 2.4 mg) remains one of the most proven weight loss medications available in 2026. The STEP-1 trial published in the New England Journal of Medicine showed patients lost an average of 14.9% of their body weight over 68 weeks. Patient reviews are broadly positive, though ongoing supply shortages and high costs remain the biggest pain points.
Wegovy also has the strongest cardiovascular safety data of any GLP-1 weight loss drug, with the SELECT trial showing a 20% reduction in major cardiac events.
How Effective Is Wegovy for Weight Loss?
Wegovy produces an average body weight reduction of 14.9% over 68 weeks at the full 2.4 mg dose, according to STEP-1 trial data published in the New England Journal of Medicine in 2021. That makes it one of the most effective prescription weight loss medications ever studied, though tirzepatide-based drugs like Zepbound have since posted higher averages in their own trials.
The STEP trial program included multiple studies across different patient populations. STEP-1 enrolled 1,961 adults[1] with obesity. STEP-2 focused on patients with type 2 diabetes.
STEP-3 added intensive behavioral therapy. Results were consistent: semaglutide 2.4 mg reliably produces double-digit weight loss.
For a patient starting at 240 pounds, a 14.9% reduction translates to roughly 36 pounds. Nearly 1 in 3 participants in STEP-1 lost 20% or more of their body weight, a threshold that approaches surgical outcomes.
| Trial | Participants | Duration | Avg. Weight Loss (Wegovy) | Avg. Weight Loss (Placebo) | Key Detail |
|---|---|---|---|---|---|
| STEP 1[1] | 1,961 adults[1] with obesity | 68 weeks | 14.9% | 2.4% | Primary weight loss trial |
| STEP 2 | 1,210 adults with T2D | 68 weeks | 9.6% | 3.4% | Diabetes[2] population |
| STEP 3 | 611 adults + behavioral therapy | 68 weeks | 16.0% | 5.7% | Combined with lifestyle intervention |
| STEP 5 | 304 adults, long-term | 104 weeks | 15.2% | 2.6% | 2-year[4] durability data |
| SELECT | 17,604 adults with CV disease | 174 weeks (mean) | 9.4% | 0.9% | 20% cardiovascular risk reduction |
The SELECT trial[5] is particularly noteworthy. It enrolled over 17,000 patients with established cardiovascular disease and demonstrated a 20% reduction in major adverse cardiovascular[5] events. No other weight loss medication has this level of heart protection data, which gives Wegovy a unique clinical advantage.
What Do Patients Report About Wegovy?
Patient reviews of Wegovy across platforms like Drugs.com, WebMD, and Reddit communities show satisfaction rates around 75 to 80%, based on aggregated user ratings through early 2026. The most frequently praised benefit is appetite suppression, followed by steady and predictable weight loss over time. For a complete cost breakdown, see our compare GLP-1 providers.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Patients consistently describe a reduction in "food noise," the constant mental preoccupation with eating. Many report that this effect begins within the first 2 weeks, even before significant weight loss occurs. The psychological relief of not constantly thinking about food is one of the most valued aspects of treatment.
But Wegovy patient experiences in 2025 and 2026 have been complicated by supply constraints. Novo Nordisk has struggled to meet demand, and many patients report difficulty filling prescriptions or being forced to restart at lower doses after gaps in supply.
What Patients Like Most
- Reliable appetite suppression: The reduction in hunger and cravings is the most commonly praised effect across all review platforms.
- Cardiovascular confidence: Patients with heart disease risk factors value the SELECT trial data showing cardiac benefits.
- Established track record: Semaglutide has been studied extensively since 2017, giving patients confidence in its safety profile.
- Weekly dosing convenience: One injection per week fits easily into most routines.
- Improved metabolic markers: Patients report better blood pressure, cholesterol, and A1C numbers at follow-up visits.
What Patients Complain About Most
- Supply shortages: Intermittent availability has been the single biggest frustration for Wegovy patients since 2023.
- GI side effects: Nausea, especially during the titration phase, is a common complaint.
- High cost without insurance: At roughly $1,350 per month, brand-name Wegovy is out of reach for many patients.
- Weight regain after stopping: Patients who discontinue often report rapid regain, which creates anxiety about long-term dependency.
- Lower efficacy vs. tirzepatide: Some patients who switch from Wegovy to Zepbound or Mounjaro report better results, leading to dissatisfaction with semaglutide.
Wegovy Side Effects: What Patients Actually Experience
The most common Wegovy side effects are gastrointestinal, with nausea affecting 44% of patients, diarrhea affecting 30%, and vomiting affecting 24% in the STEP-1 trial, according to FDA prescribing information. These rates are higher than what patients on tirzepatide typically report, though most patients say the symptoms are manageable and improve with time.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Patient reviews consistently note that nausea is worst during the dose escalation period, particularly at the 1.0 mg and 1.7 mg steps. Most patients report that symptoms become tolerable or disappear entirely within 2 to 4 weeks of reaching a stable dose.
Strategies that patients recommend for managing side effects include eating bland foods, avoiding large or fatty meals, taking the injection at bedtime, and staying well hydrated. Some patients also report that ginger supplements and anti-nausea medications prescribed by their provider help during the adjustment period.
| Side Effect | STEP-1 Trial Incidence | Patient-Reported Severity | Typical Duration |
|---|---|---|---|
| Nausea | 44% | Moderate during titration, mild at maintenance | 2 to 4 weeks per dose increase |
| Diarrhea | 30% | Mild to moderate | 1 to 2 weeks |
| Vomiting | 24% | Moderate during titration | 1 to 3 weeks |
| Constipation | 24% | Mild to moderate | Variable. ongoing for some |
| Abdominal pain | 20% | Mild | 1 to 2 weeks |
| Headache | 14% | Mild | First 1 to 2 weeks |
| Fatigue | 11% | Mild | First month |
The discontinuation rate due to side effects in the STEP-1 trial was approximately 7% for the semaglutide group, compared to 3.1% for placebo. That means the vast majority of patients who start Wegovy are able to continue treatment despite initial GI discomfort.
Wegovy Supply Shortage: What Patients Need to Know
Wegovy has experienced intermittent supply shortages since its launch, with the most significant disruptions occurring throughout 2024 and into early 2025, according to FDA drug shortage database listings. As of March 2026, supply has improved but certain dose strengths (particularly 1.0 mg and 1.7 mg titration doses) remain periodically constrained in some regions.
Patients report that supply issues create real clinical problems. Gaps in treatment mean restarting from lower doses, which extends the titration timeline and delays therapeutic benefit. Some patients describe losing months of progress due to supply-related interruptions.
For patients who can't reliably access Wegovy, compounded semaglutide is an alternative that has grown in popularity. Compounding pharmacies prepare semaglutide in injectable form at a fraction of the brand-name cost. But compounded versions aren't FDA-approved Wegovy and quality can vary by pharmacy.
Is Wegovy Worth the Cost?
Wegovy carries a list price of approximately $1,350 per month without insurance, according to Novo Nordisk's published pricing as of early 2026. That makes it one of the more expensive weight loss medications on the market, and cost is the number one barrier to access that patients cite in reviews.
Insurance coverage for Wegovy has expanded over the past year, but it remains inconsistent. Many commercial plans now cover it with prior authorization, though approval often requires documented BMI thresholds and evidence of failed lifestyle interventions. Medicare still doesn't cover anti-obesity medications.
Compounded semaglutide provides a lower-cost alternative for patients priced out of brand-name Wegovy. Providers like FormBlends offer compounded semaglutide starting at $149 per month, with medical provider oversight included.
Disclosure: FormBlends is a licensed telehealth provider that offers compounded semaglutide. This article is an independent drug review, and our clinical assessments are based on published trial data regardless of the medications we offer.
| Option | Monthly Cost | Notes |
|---|---|---|
| Wegovy (brand, no insurance) | ~$1,350 | Novo Nordisk list price |
| Wegovy (with commercial insurance) | $25 to $200 | Prior authorization typically required |
| Novo Nordisk savings offer | $0 to $25 | For eligible commercially insured patients |
| Compounded semaglutide (FormBlends) | $149/mo | Same active ingredient. not brand-name Wegovy |
How Does Wegovy Compare to Alternatives?
Wegovy produces 14.9% average weight loss at the 2.4 mg dose, which places it behind Zepbound (20.9%) but well ahead of older options like Saxenda (8%) and Contrave (5 to 6%), according to published clinical trial data from the New England Journal of Medicine. Its unique advantage is the SELECT cardiovascular outcomes data, which no competing weight loss medication has matched.
For patients choosing between Wegovy and Zepbound, the decision often comes down to insurance coverage, cardiovascular risk profile, and individual response. Some patients respond better to semaglutide than tirzepatide, and vice versa. There's no reliable way to predict which will work best for a given individual without trying one.
The comparison table below outlines the key differences across major weight loss medications available in 2026.
| Medication | Active Ingredient | Mechanism | Avg. Weight Loss | CV Benefit Proven | Monthly Cost (no insurance) |
|---|---|---|---|---|---|
| Wegovy | Semaglutide 2.4 mg | GLP-1 agonist | 14.9% | Yes (SELECT trial) | ~$1,350 |
| Zepbound | Tirzepatide | GLP-1 + GIP dual agonist | 20.9% | Under study | ~$1,060 |
| Mounjaro | Tirzepatide | GLP-1 + GIP dual agonist | 20.9% (off-label) | Under study | ~$1,060 |
| Ozempic | Semaglutide 1.0 mg | GLP-1 agonist | ~10% (off-label for weight) | Yes (SUSTAIN-6[6]) | ~$950 |
| Saxenda | Liraglutide | GLP-1 agonist | 8% | No | ~$1,350 |
For a more detailed comparison, see our semaglutide vs. alternatives guide and our semaglutide before-and-after results page.
Frequently Asked Questions About Wegovy
How much weight can you lose on Wegovy in 3 months?
Most patients lose between 5% and 10% of their body weight in the first 3 months on Wegovy, based on STEP trial trajectory data. For a 220-pound patient, that's roughly 11 to 22 pounds. Weight loss accelerates as the dose increases through the titration schedule.
Is Wegovy better than Ozempic for weight loss?
Wegovy (semaglutide 2.4 mg) produces more weight loss than Ozempic (semaglutide 1.0 mg or 2.0 mg) because it uses a higher dose. The active ingredient is identical, but Wegovy is FDA-approved specifically for weight management while Ozempic is approved for type 2 diabetes.
What are the most common Wegovy side effects?
Nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%) are the most common side effects from STEP-1 trial data. These are typically worst during dose escalation and improve within 2 to 4 weeks at each new dose level.
Why is Wegovy so hard to find?
Demand for Wegovy has exceeded Novo Nordisk's manufacturing capacity since the drug launched. While supply has improved significantly by early 2026, intermittent shortages of certain dose strengths still occur in some regions. Patients can check availability through their pharmacy or consider compounded semaglutide as an alternative.
Does Wegovy work for everyone?
No. In the STEP-1 trial, approximately 9% of patients in the semaglutide group did not lose at least 5% of their body weight. Individual response varies based on genetics, metabolic factors, dietary habits, and adherence to the medication.
How long do you stay on Wegovy?
Wegovy is intended as a long-term treatment. The STEP-1 extension data and the STEP-4[7] withdrawal trial both showed that patients who stop semaglutide tend to regain weight. Most providers recommend ongoing treatment alongside lifestyle modifications for sustained results.
Can you drink alcohol on Wegovy?
There's no absolute contraindication to alcohol with Wegovy. But patients commonly report lower alcohol tolerance and increased nausea when drinking, especially during titration. Most providers recommend limiting alcohol intake, particularly in the first few months of treatment.
Is Wegovy safe for people with heart problems?
The SELECT trial specifically studied semaglutide in over 17,000 patients with established cardiovascular disease and showed a 20% reduction in major adverse cardiac events. Wegovy is considered safe and potentially beneficial for patients with heart disease, though individual assessment by a provider is always recommended.
For more information, explore our complete semaglutide side effects guide, semaglutide cost breakdown, and our semaglutide for weight loss overview.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. [PubMed | ClinicalTrials.gov | DOI]
- Marso SP, Daniels GH, Tanaka K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. [PubMed | ClinicalTrials.gov | DOI]
- Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity (STEP 4). JAMA. 2021;325(14):1414-1425. [PubMed | ClinicalTrials.gov | DOI]